Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Clinical trial investigators violate EU regulations: Entries in EU Register are incomplete

2018-09-21 Compliance of pharma companies is relatively good, but very poor for university research groups. Research funders should make allocation of further funding dependent on data transparency.

read more Link to \Clinical trial investigators violate EU regulations: Entries in EU Register are incomplete\""

Screening for depression: benefit remains questionable

2018-09-17 IQWiG still sees no basis for introducing a screening programme. There were neither comments on the preliminary report nor other new findings.

read more Link to \Screening for depression: benefit remains questionable\""

DMP “type 1 diabetes”: Institute recommends revision

2018-09-10 New guidelines change the results of the final report versus the preliminary report: Stronger focus, among other things, on the avoidance of hypoglycaemia by means of modern Technologies.

read more Link to \DMP “type 1 diabetes”: Institute recommends revision\""

Biomarker tests in breast cancer: New study data indicate advantage for certain patients

2018-09-05 TAILORx is the first available study with long-term follow-up suitable for the assessment. The Oncotype DX test apparently identifies women who can omit chemotherapy.

read more Link to \Biomarker tests in breast cancer: New study data indicate advantage for certain patients\""

Negative pressure wound therapy: violation of ethical and scientific standards

2018-08-28 The treatment has been used in hospitals for over 20 years, and more than 100 studies have been completed worldwide. But manufacturers and researchers are concealing a large proportion of the results.

read more Link to \Negative pressure wound therapy: violation of ethical and scientific standards\""

Continuous passive motion for knee or shoulder joints: advantage only in two therapeutic indications

2018-07-30 Less pain in stiff shoulders and improved mobility after total knee replacement – but the final report does not confirm greater benefit in rotator cuff tears.

read more Link to \Continuous passive motion for knee or shoulder joints: advantage only in two therapeutic indications\""

Haemophilia A and sialorrhoea: comparator therapies not implemented, added benefit not proven

2018-07-02 In two early benefit assessments, IQWiG was unable to derive an added benefit from the data presented because current standards of care were not implemented in the studies.

read more Link to \Haemophilia A and sialorrhoea: comparator therapies not implemented, added benefit not proven\""

Non-invasive prenatal diagnosis can reliably detect trisomy 21

2018-06-27 NIPD can reduce the number of invasive tests and hence the number of test-related miscarriages in women whose foetuses are at an increased risk of trisomy 21.

read more Link to \Non-invasive prenatal diagnosis can reliably detect trisomy 21\""

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
V18-01 Guideline synopsis for the DMP “type 2 diabetes” on the report plan 2018-09-13
N17-01A Negative pressure wound therapy for wounds healing by secondary Intention on the preliminary report 2018-09-25
S18-01 Newborn screening for sickle cell disease on the report plan 2018-10-02

Calls for tenders advertised

Calls for tenders advertised

In general, calls for tenders are published in German. Interested parties can check current calls for tenders on the German website.


Easily understandable information for patients and the general community

Bosutinib (Bosulif) for the treatment of chronic myeloid leukemia

Bosutinib (trade name: Bosulif) has been approved in Germany since March 2013 for the treatment of Philadelphia chromosome-positive, chronic myeloid leukemia in adults who have had treatment before. Since May 2018, the drug has also been approved for the treatment of the chronic phase in people with newly diagnosed chronic myeloid leukemia.   read more (Link to \Bosutinib (Bosulif) for the treatment of chronic myeloid leukemia\"" ‚Äì opens in a new window)


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close